The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 'war games': the computer program that could help save your job

Wed, 11th Nov 2020 12:23

* Tech firm creates game to simulate impact of COVID layoffs

* 'Broad-front' cost-cutting strategy seen as more effective

* World of work on brink of revolution, creator says

By Sinead Cruise

LONDON, Nov 11 (Reuters) - Bank of England Chief Economist
Andy Haldane has signed up to judge the winner of a 'war game'
designed to help firms find alternatives to mass layoffs in the
face of a coronavirus-driven slowdown.

Confronted with the most unpredictable pandemic in memory,
cost-conscious firms have already axed millions of staff
worldwide, while UK redundancies hit a record high of 314,000 in
the quarter to Sept. 30, official data showed on Tuesday.

Unilever-owned tech firm uFlexReward created the
COVID-19 War Game to allow executives to explore the impact of
huge job cuts on their future earnings prospects.

"Many companies across the UK are facing financial strains
as a result of the COVID crisis," Haldane told Reuters.

"Simulation tools can help us understand how best to
alleviate these strains while preserving jobs, in a way that
helps both businesses when making difficult commercial decisions
and policymakers when making difficult economic decisions."

The game, designed during Britain's first lockdown this year
and available free to play on the uFlexReward website, calls on
players to devise a strategy to cut people costs of a fictional
firm by 20%.

Participants weigh up the pros and cons of large-scale
redundancies versus alternatives, for the long-term benefit of
the firm as well as the broader economy.

It collates staff salaries, pensions, bonuses and share
awards into one real-time cost-base, helping players see
different ways of trimming overheads more clearly.

This can include making lots of smaller cost cuts in a
so-called 'broad-front' approach, rather than one large saving
in more focused cuts like scrapping entire business units or the
staff bonus pool.

Financial firms have historically slashed highly paid
workforces on the eve of recession, only to rehire rapidly when
the economy rebounds.

Swapping this convention for a broad-front approach could
minimise the risks that employers end up understaffed and
under-skilled when the recovery kicks off, uFlexReward Chief
Executive Ken Charman said.

'CHANGE IS COMING'

Employers in multiple sectors are facing the prospect of a
broader revolution in the world of work, triggered by technology
and mass remote working.

"We are still stuck in a very Victorian view of what work is
- with fixed working days, for a single employer and in a
typically narrow role," Charman said.

"But change is coming that will allow people to be several
things at once ... if companies lose people who are highly
trained, experienced and loyal, they won't get them back," he
said.

Charman hopes the game might persuade employers to waive or
cut dividends as well as executive pay increases, and offer
job-sharing, reduced hours or part-time roles with flexibility
to work elsewhere to staff who might otherwise end up
unemployed.

Pushing through alternatives to mass layoffs will require
strong leadership and communication, particularly when thousands
of employee contracts need to be renegotiated, but retaining
staff could leave firms better placed when the recovery begins,
Charman said.

"Executives need to be willing to abandon the old
conventions; there will be resistance and they've got to be able
to convince people this is in their best interests," he said.

"Employers, big companies and big financial institutions are
part of our critical national infrastructure as much as the
National Grid. They are the engines of our growth, but they are
under threat."

Judging of the head-to-head version of the game, featuring
teams made up of executives from Unilever and NYSE-listed
technology services provider Endava, will take place on
Dec. 3.

Together with Haldane, AstraZeneca senior vice
president of reward and inclusion Rebekah Martin, Unilever head
of global reward Constantina Tribou, and author David Goodhart
are among those judging the strategies.
($1 = 0.7706 pounds)
(Reporting by Sinead Cruise; Editing by Jan Harvey)

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.